FU97 Xenograft Model Service for Gastric Cancer

FU97 Xenograft Model Service for Gastric Cancer provides a robust preclinical platform for evaluating therapeutic efficacy against AFP-producing gastric carcinoma. Alfa Cytology delivers comprehensive FU97 xenograft model development and pharmacological evaluation services, enabling researchers to advance novel anti-cancer compounds from early-stage screening through preclinical validation with standardized protocols and rigorous quality control.

Overview of FU97 Xenograft Model for Gastric Cancer

The FU97 cell line was established from a poorly differentiated gastric adenocarcinoma in a 66-year-old Japanese female patient presenting with elevated serum alpha-fetoprotein (AFP) levels (2,266 ng/mL prior to operation). This cell line is notable for maintaining AFP production and tumorigenicity in vitro, representing a unique subset of gastric cancer characterized by hepatoid differentiation and aggressive metastatic behavior. FU97 xenograft models faithfully recapitulate the proliferative characteristics and AFP-secreting phenotype of the original tumor, providing a physiologically relevant system for preclinical drug evaluation. The model demonstrates reliable engraftment in immunodeficient murine hosts and supports longitudinal assessment of tumor growth kinetics, making it particularly valuable for studying targeted therapies against AFP-expressing gastric malignancies.

FU97 xenograft models serve as an essential tool for investigating the biological mechanisms underlying AFP-producing gastric cancer, a rare but clinically significant subtype associated with poor prognosis and resistance to conventional chemotherapy. These models enable systematic evaluation of therapeutic interventions through measurable endpoints including tumor volume regression, AFP biomarker dynamics, and metastatic potential assessment. The epithelial-like morphology and adherent growth pattern of FU97 cells facilitate standardized subcutaneous or orthotopic implantation procedures, ensuring reproducible tumor formation and consistent pharmacological response profiles across study cohorts. Researchers utilize this model to screen novel molecular targeted agents, immunotherapeutic approaches, and combination regimens specifically tailored to hepatoid gastric carcinoma phenotypes.

Figure 1. A subset of human GC cell lines is susceptible to single inhibition of BCLXL or MCL1. (Zhang, Li-Ping, et al., 2025)

Cell Line Information: FU97

FU97 is a human gastric cancer cell line established from a poorly differentiated adenocarcinoma with hepatoid differentiation characteristics. The cell line maintains AFP production capacity and demonstrates epithelial-like morphology with adherent growth properties. Below is the comprehensive cell line profile:

Our Services

Alfa Cytology specializes in preclinical gastric cancer model development, offering end-to-end FU97 xenograft services encompassing cell line authentication, model establishment, in vivo pharmacological evaluation, and comprehensive endpoint analysis. Our experienced scientific team ensures reproducible tumor formation, standardized dosing regimens, and high-quality data delivery to accelerate your oncology drug development pipeline from lead optimization through IND-enabling studies.

Workflow of FU97 Xenograft Model Construction

FU97 xenograft model construction follows a standardized, multi-phase workflow designed to ensure reproducible tumor growth, animal welfare compliance, and reliable pharmacological data generation. The process integrates cell line quality control, precise implantation techniques, and systematic monitoring protocols.

1. Cell Line Preparation and Authentication: FU97 cells are recovered from cryopreservation, expanded under standardized culture conditions, and authenticated via STR profiling and mycoplasma testing to confirm identity and sterility prior to implantation.
2. Host Animal Selection and Acclimation: Immunodeficient mice (typically NOD-SCID or nude mice) are selected based on study requirements and acclimated for 7-14 days under controlled environmental conditions to minimize stress-related variables.
3. Tumor Cell Preparation for Implantation: Exponentially growing FU97 cells are harvested using trypsin-EDTA, washed, and resuspended in serum-free medium mixed with Matrigel at optimized ratios to enhance engraftment efficiency and tumor take rates.
4. Subcutaneous or Orthotopic Implantation: Cell suspensions are implanted subcutaneously into the flank region (typically 1x10^6 to 5x10^6 cells per site) or orthotopically into the gastric wall under anesthesia, depending on the study design and endpoint objectives.
5. Post-Implantation Monitoring and Randomization: Mice are monitored daily for health status; upon reaching palpable tumor volumes (typically 50-100 mm^3), animals are randomized into treatment groups to ensure balanced baseline tumor volumes across cohorts.
6. Therapeutic Intervention and Dosing: Test compounds are administered via appropriate routes (oral gavage, intraperitoneal, or intravenous injection) according to predefined dosing schedules, with vehicle control groups included for comparative analysis.
7. Tumor Measurement and Biomarker Collection: Tumor dimensions are measured by caliper twice weekly to calculate volume; serial blood samples may be collected for AFP biomarker analysis to monitor treatment response and pharmacodynamic effects.
8. Endpoint Analysis and Tissue Collection: At study termination, tumors are excised, weighed, and processed for histopathological analysis (H&E staining, IHC), while additional tissues are snap-frozen or fixed for molecular and biomarker investigations.
9. Data Compilation and Reporting: All data including tumor growth curves, body weight changes, biomarker dynamics, and histological findings are compiled into a comprehensive study report with statistical analysis to support decision-making.

Figure 2: Schematic workflow illustrating the derivation and construction of the FU97 Xenograft Model at Alfa Cytology.

Case Study-FU97 Xenograft Model Development

In a representative FU97 xenograft model development study, immunodeficient mice were implanted subcutaneously with authenticated FU97 cells and monitored for tumor establishment and growth kinetics. The model demonstrated consistent tumor take rates with measurable AFP secretion correlating with tumor burden, enabling reliable assessment of therapeutic intervention effects on tumor progression and biomarker modulation. Pharmacological evaluation of reference compounds showed dose-dependent tumor growth inhibition, validating the model's utility for preclinical efficacy screening. Comprehensive endpoint analysis including tumor volume measurements, body weight monitoring, and histopathological examination confirmed the model's suitability for supporting oncology drug development programs targeting AFP-producing gastric malignancies.

Why Choose Alfa Cytology?

Alfa Cytology provides comprehensive, high-quality FU97 xenograft model services backed by scientific expertise, rigorous quality standards, and a commitment to accelerating preclinical oncology research.

• Extensive experience in gastric cancer xenograft model development with validated FU97 cell line authentication and quality control protocols.
• Standardized tumor implantation procedures ensuring high engraftment rates and reproducible tumor growth kinetics across study cohorts.
• Comprehensive endpoint analysis capabilities including tumor volume tracking, AFP biomarker monitoring, and histopathological evaluation.
• Flexible study design options accommodating subcutaneous and orthotopic implantation, combination therapy assessment, and customized dosing schedules.
• Dedicated project management with regular progress updates, transparent communication, and timely delivery of comprehensive study reports.
• Strict adherence to animal welfare guidelines and regulatory compliance standards for all preclinical in vivo studies.

Contact Us

Partner with Alfa Cytology to advance your gastric cancer therapeutic pipeline using our validated FU97 xenograft model platform. Please reach out to us today via our inquiry form or email to learn more about our FU97 Xenograft Model services.

For research use only. Not intended for any clinical use.